Researcher Profile

Researcher Profile

W. Christopher Ehmann, MD

W. Christopher Ehmann, MD

Professor, Department of Medicine
Division of Hematology and Oncology
Disease Teams:
Bone Marrow Transplantation
Leukemia and Lymphoma
wce4@psu.edu

Research Interests

  • Therapeutics
  • Acute Myeloid Leukemia
  • Rituximab
  • T-Lymphocytes
  • HIV
  • B-Cell Lymphoma
  • Survival
  • Drug Therapy
  • Transplants
  • Leukemia
  • Non-Hodgkin's Lymphoma
  • Zidovudine

Clinical Trials

Protocol for a Research Database for Hematopoietic Cell Transplantation, other Cellular Therapies and Marrow Toxic Injuries.
Blood and Bone Marrow Collection from Patients with Hematological Malignancies for Study of Anti-Tumor Immunity
Collection of Blood for Investigation and Characterization of Circulating Tumor Cells (CTCs) in Cancer Patients with Microdevices
bcr-abl PCR response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia in Stable Chronic Phase.
Clofarabine followed by Fludarabine, Busulfan, Total-Body Irradiation and Hematopoietic Stem Cell Transplant with Post-Transplant Cyclophosphamide for Non-remission Acute Myeloid Leukemia
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) In Combination with Polatuzumab Vedotin in Patients with B-Cell Non-Hodgkin Lymphoma
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries with Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
T-Cell Exhaustion in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia
Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation

Recent Publications

2021

Gvozdjan, K, Casey, H, Mowery, C, Kumer, L, Fisher, C, Tyler, J, Bayerl, MG, Malysz, J, Naik, S, Rybka, W, Ehmann, C, Claxton, D, Mineishi, S, Baker, M, Hong, Z & Shike, H 2021, 'Unexpected Short-Tandem-Repeat Patterns in Post-Transplant Chimerism Testing: Investigation of 3 Cases with Help from Forensic Science', Laboratory Medicine, vol. 51, no. 6, pp. 635-641. https://doi.org/10.1093/LABMED/LMAA022

2020

Zheng, H, Mineishi, S, Claxton, D, Zhu, J, Zhao, C, Jia, B, Ehmann, WC, Rybka, WB, Naik, S, Songdej, N, Drabick, JJ & Hohl, RJ 2021, 'A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia', American Journal of Hematology, vol. 96, no. 2, pp. E46-E50. https://doi.org/10.1002/ajh.26043

2019

Jia, B, Zhao, C, Rakszawski, KL, Claxton, DF, Christopher Ehmann, W, Rybka, WB, Mineishi, S, Wang, M, Shike, H, Bayerl, MG, Sivik, JM, Schell, TD, Drabick, JJ, Hohl, RJ & Zheng, H 2019, 'Eomes+T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia', Cancer Research, vol. 79, no. 7, pp. 1635-1645. https://doi.org/10.1158/0008-5472.CAN-18-3107
Zhao, C, Jia, B, Wang, M, Schell, TD, Claxton, DF, Ehmann, WC, Rybka, WB, Mineishi, S, Naik, S, Songdej, N, Sivik, JM, Hohl, RJ, Zeng, H & Zheng, H 2020, 'Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML', British Journal of Haematology, vol. 188, no. 5, pp. 674-684. https://doi.org/10.1111/bjh.16228
Spurgeon, SE, Sharma, K, Claxton, DF, Ehmann, C, Pu, J, Shimko, S, Stewart, A, Subbiah, N, Palmbach, G, LeBlanc, F, Latour, E, Chen, YY, Mori, M, Hasanali, Z & Epner, EM 2019, 'Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma', British Journal of Haematology, vol. 186, no. 6, pp. 845-854. https://doi.org/10.1111/bjh.16008

2018

Jia, B, Wang, L, Claxton, DF, Ehmann, WC, Rybka, WB, Mineishi, S, Rizvi, S, Shike, H, Bayerl, M, Schell, TD, Hohl, RJ & Zheng, H 2018, 'Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients', Blood Cancer Journal, vol. 8, no. 3, 34. https://doi.org/10.1038/s41408-018-0069-4
Wang, L, Jia, B, Claxton, DF, Ehmann, WC, Rybka, WB, Mineishi, S, Naik, S, Khawaja, MR, Sivik, J, Han, J, Hohl, RJ & Zheng, H 2018, 'VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML', OncoImmunology, vol. 7, no. 9, e1469594. https://doi.org/10.1080/2162402X.2018.1469594

2017

Zhu, L, Kong, Y, Zhang, J, Claxton, DF, Ehmann, WC, Rybka, WB, Palmisiano, ND, Wang, M, Jia, B, Bayerl, M, Schell, TD, Hohl, RJ, Zeng, H & Zheng, H 2017, 'Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia', Journal of Hematology and Oncology, vol. 10, no. 1, 124. https://doi.org/10.1186/s13045-017-0486-z
Teye, EK, Sido, A, Xin, P, Finnberg, NK, Gokare, P, Kawasawa, YI, Salzberg, AC, Shimko, S, Bayerl, M, Ehmann, WC, Claxton, DF, Rybka, WB, Drabick, JJ, Wang, HG, Abraham, T, El-Deiry, WS, Brodsky, RA, J.Hohl, R & Pu, JJ 2017, 'PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features', Oncotarget, vol. 8, no. 18, pp. 29887-29905. https://doi.org/10.18632/oncotarget.15136

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)